Companies › Privo Technologies
1 active drug program in 3 registered trials: 3 Phase 2; Oncology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PRV111 (Cisplatin Transmucosal System) Transmucosal cisplatin patch delivery system | SLC31A2 | Phase 2 | Oral Squamous Cell Carcinoma | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05893888 | PRV111 (Cisplatin Transmucosal System) | Phase 2 | Oral Squamous Cell Carcinoma | Oncology | May 2027 |
| NCT05893888 | PRV111 (Cisplatin Transmucosal System) | Phase 2 | Oral Squamous Cell Carcinoma | Oncology | May 2027 |
| NCT05893888 | PRV111 (Cisplatin Transmucosal System) | Phase 2 | Oral Squamous Cell Carcinoma | Oncology | May 2027 |
–
iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.